1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574


Delayed Nasdaq Copenhagen  -  05/25 10:17:27 am EDT
77.80 DKK   +3.18%
09:44aViroGates announces the CE-IVD accreditation of its finger-prick blood-testing product, suPARnostic® POC+
05/10VIROGATES : Healthy growth
05/04VIROGATES ANNOUNCES ITS INTERIM REPORT FOR Q1, 2022 : Record quarterly revenue and doubling of clinical customers
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates publishes the financial calendar for 2022

12/22/2021 | 09:03am EDT

COMPANY ANNOUNCEMENT - No. 25-2021 - 22 December 2021

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today publishes the financial calendar for 2022 with the following key dates:



23 March 2022

Deadline for submission of business to be transacted at the 2022 Annual General Meeting

23 March 2022

Annual Report 2021

28 April 2022

Annual General Meeting

4 May 2022

Interim Report Q1 2022

18 August 2022

Interim Report H1 (Q2) 2022

10 November 2022

Interim Report Q1-Q3 2022

The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after release.

Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 23 March 2022 via email to jk@virogates.com.

The announcement can be found at https://www.virogates.com/investor/announcements 

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 750 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.


  • Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com


© Ritzau Denmark, source Ritzau English Regulatory Releases

All news about VIROGATES A/S
09:44aViroGates announces the CE-IVD accreditation of its finger-prick blood-testing product,..
05/10VIROGATES : Healthy growth
05/04VIROGATES ANNOUNCES ITS INTERIM REPO : Record quarterly revenue and doubling of clinical c..
05/04ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
05/03Invitation to ViroGates' Q1 2022 presentation
04/28Resolutions from the Annual General Meeting of ViroGates A/S
04/28ViroGates A/S Announces Board Changes
04/19VIROGATES A/S : High blood sugar and suPAR levels independently worsen COVID-19 outcomes
04/18ViroGates announces a current total of 33 clinical routine hospital customers and adjus..
04/13ViroGates gives notice to convene the Annual General Meeting on 28 April 2022
More news
Net income
Net Debt
P/E ratio
Capitalization 239 M 34,4 M 34,4 M
EV / Sales -1
EV / Sales 0
Nbr of Employees 14
Free-Float 47,5%
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Patrik Olof Dahlén Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S-47.64%34
BGI GENOMICS CO., LTD.-21.41%4 251
SEEGENE, INC.-30.98%1 718